Oxford Biomedica Maintains Full-Year Outlook Despite Widening First-Half Loss
Companies

Oxford Biomedica Maintains Full-Year Outlook Despite Widening First-Half Loss

Revenue rose 9.2% to £79.9m and 17 new clients were signed, but a 22% jump in cost of sales and a £7.6m impairment pushe...

Declan Byrne 👁 53 💬 0
What to Watch as 30 CAC 40 Companies Report Half-Year Results This Week
Companies

What to Watch as 30 CAC 40 Companies Report Half-Year Results This Week

Three-quarters of France's flagship index publish interim results in a single week, with investors parsing guidance upgr...

Declan Byrne 👁 62 💬 0